

POINT-COUNTERPOINT

Pathophysiological Roles of Ductular Reaction in Liver Inflammation and Hepatic Fibrogenesis

Keisaku Sato,^{1,*} Linh Pham,^{1,2} Shannon Glaser,³ Heather Francis,^{1,4} and Gianfranco Alpini^{1,4,*}

¹Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana; ²Department of Science and Mathematics, Texas A&M University – Central Texas, Killeen, Texas; ³Department of Medical Physiology, Texas A&M University College of Medicine, Bryan, Texas; and ⁴Richard L. Roudebush VA Medical Center, Indianapolis, Indiana

See counterpoint on page 806.

Ductular reaction is referred to as expansion of proliferative and reactive cells that express biliary markers, such as cytokeratin (CK)-7 and CK-19.¹ Ductular reaction is identified by histologic staining in liver specimen of patients with various liver diseases including cholangiopathies, viral hepatitis, and alcoholic and nonalcoholic liver diseases.¹ Ductular reaction is clinically recognized as bile duct hyperplasia; however, the term “ductular reaction” is more commonly used in recent studies to define enhanced intrahepatic bile duct mass that can be attributed to the proliferation of cholangiocytes and/or transdifferentiation of various hepatic cells.¹ It is known that ductular reaction is associated with liver fibrosis and thought to be caused by expansion of hepatic progenitor cells (HPCs).² Accumulating evidence indicates that ductular reaction (ie, expansion of CK-7⁺ or CK-19⁺ cells) can be caused not only by HPCs, but also other hepatic cells. Bile duct epithelial cells, cholangiocytes, express CK-7 and CK-19 and proliferate during bile duct injury, which is identified as ductular reaction.¹ Furthermore, in certain pathologic conditions, hepatocytes can transdifferentiate into cholangiocyte-like cells expressing CK-7 or CK-19 to compensate the loss of cholangiocyte numbers and functions.³ Ductular reaction can be induced by expansion of HPCs, cholangiocytes, or hepatocytes, and functional roles of ductular reaction may differ depending on liver diseases or origins of expanding cells. This

section discusses the pathophysiological roles of ductular reaction in liver diseases.

Hepatic cells communicate with each other to coordinate pathophysiological responses against liver injury via secreting cytokines, chemokines, or extracellular vesicles.⁴ In the portal area and the HPC niche, HPCs, hepatic stellate cells, and macrophages secrete and receive cytokines and growth factors leading to liver inflammation and regeneration.² Ductular reaction is associated with portal inflammation and neutrophil infiltration in alcoholic hepatitis, and the cells in ductular reaction (CK-7⁺ cells) express elevated neutrophil recruiting chemokines and HPC markers.⁵ In nonalcoholic fatty liver disease, portal inflammation is strongly correlated with liver fibrosis levels and ductular reaction with increased portal infiltration of macrophages and lymphocytes.⁶ Ductular reaction and increased portal macrophage infiltration can also be identified in cholestatic liver injury.⁷ Cholangiocytes become senescent during cholestatic liver injury, including primary sclerosing cholangitis (PSC).⁸ Senescent cholangiocytes function as a senescence-associated secretory phenotype secreting various cytokines, such as interleukin-6 and transforming growth factor- β 1.⁸ Interleukin-6 promotes cholangiocyte proliferation and activates macrophages leading to ductular reaction and liver inflammation.⁹ These findings indicate the close relationship between ductular reactive cells (ie, HPCs and cholangiocytes) and portal infiltration and inflammation.

Liver fibrosis is observed in various liver diseases, and the association of

expansion of the HPC niche (ie, ductular reaction) with liver fibrosis has been identified.² Liver fibrosis is a hallmark in cholangiopathies, such as PSC, primary biliary cholangitis, and biliary atresia, and ductular reaction is identified along with liver fibrosis.¹ Expansion of CK-7⁺ or CK-19⁺ cells is found in liver sections of patients with hepatitis B or C virus infection, and ductular reaction levels are correlated with liver fibrosis levels.¹⁰ Ductular reaction levels also correlate with poor prognosis of patients with alcoholic hepatitis and can be used to predict survival rates of patients in severe conditions.¹¹ A higher grade of ductular reaction determined by histologic CK-7 staining is correlated with higher fibrosis stages in patients with nonalcoholic fatty liver disease.⁶ It is also suggested that ductular reaction is associated with hepatocellular carcinoma. Peritumoral ductular reaction significantly correlates with hepatic inflammation, liver fibrosis, TNM stages, and poor prognosis,¹² indicating the association of ductular reaction with the pathophysiology of various liver diseases.

Liver fibrosis is caused by accumulated extracellular matrix (ECM) secreted from activated hepatic stellate cells or myofibroblasts, major sources of ECM secretion. During PSC, senescent cholangiocytes secrete transforming growth factor- β 1, which promotes hepatic stellate cell proliferation and activation leading to ECM accumulation and liver fibrosis.¹³ Because ductular reaction and liver fibrosis are closely associated and mediated by ductular reactive cells, including cholangiocytes, these cells can be a therapeutic target for liver fibrosis. Inhibition of biliary senescence




Figure 1. Association of ductular reaction with portal inflammation and liver fibrosis in liver diseases. Expansion of CK-7⁺ or CK-19⁺ cells, which is referred to as ductular reaction, is commonly observed in various liver diseases. The origin of ductular reactive cells includes cholangiocytes, hepatocytes, and hepatic progenitor cells. Ductular reactive cells induce portal infiltration of immune cells, such as macrophages and neutrophils, leading to portal inflammation. Ductular reaction is associated with hepatic stellate cell activation leading to secretion of ECM and liver fibrosis. Cholangiocytes transdifferentiate into myofibroblast-like cells contributing to hepatic fibrogenesis via epithelial-to-mesenchymal transition. Figure created with BioRender (Toronto, Canada).

by p16 Vivo-Morpholino administration downregulated cholangiocyte senescence-associated secretory phenotype secretion with attenuated ductular reaction and liver fibrosis in PSC mouse models.¹⁴ Cholangiocytes undergo epithelial-to-mesenchymal transition and transform into myofibroblast-like profibrogenic phenotypes secreting robust ECM components contributing to hepatic fibrogenesis in cholestatic liver injury.¹⁵ Inhibition of cholangiocyte epithelial-to-mesenchymal transition by vimentin Vivo-Morpholino attenuated ductular reaction and liver fibrosis in PSC mouse models.¹⁵ Vimentin knock-down also ameliorated liver inflammation and serum transforming growth factor- β 1 levels in PSC mice.¹⁵ These findings support the close association of ductular reaction and liver fibrosis, and inhibition of ductular reaction can be therapeutic in liver diseases.

Current studies show the pathophysiological roles of ductular reaction

and its close association with hepatic inflammation and liver fibrosis in various liver diseases (Figure 1). In PSC, inhibiting cholangiocyte senescence or epithelial-to-mesenchymal transition could be a novel therapeutic approach to improve liver conditions by attenuating ductular reaction and liver fibrosis, showing the potentials of cholangiocytes as a promising target of liver diseases. However, not only cholangiocytes but also HPCs and hepatocytes are involved in ductular reaction. The HPC niche is associated with liver fibrosis,² and elevated HPC marker expression (ie, expansion of the HPC niche) is associated with neutrophil infiltration and liver inflammation.⁵ Hepatocytes transdifferentiate into biliary-like phenotypes during cholestatic liver injury.³ Although it is not fully elucidated how HPCs and hepatocytes contribute to the pathophysiology of ductular reaction and liver fibrosis, targeting HPCs and hepatocytes might be

another therapeutic approach in liver diseases.

In conclusion, ductular reaction is closely related to liver inflammation and fibrosis and the pathophysiology of liver diseases. Understanding the full dynamic role of ductular reaction during liver injury and identification of potential targets associated with ductular reaction are of paramount significance.

References

1. Sato K, Marzioni M, Meng F, et al. Ductular reaction in liver diseases: pathological mechanisms and translational significances. *Hepatology* 2019;69:420–430.
2. Williams MJ, Clouston AD, Forbes SJ. Links between hepatic fibrosis, ductular reaction, and progenitor cell expansion. *Gastroenterology* 2014;146:349–356.
3. Nejak-Bowen K. If it looks like a duct and acts like a duct: on the role of reprogrammed hepatocytes

- in cholangiopathies. *Gene Expr* 2020;20:19–23.
4. Sato K, Kennedy L, Liangpunsakul S, et al. Intercellular communication between hepatic cells in liver diseases. *Int J Mol Sci* 2019;20:2180.
 5. Aguilar-Bravo B, Rodrigo-Torres D, Arino S, et al. Ductular reaction cells display an inflammatory profile and recruit neutrophils in alcoholic hepatitis. *Hepatology* 2019;69:2180–2195.
 6. Gadd VL, Skoien R, Powell EE, et al. The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease. *Hepatology* 2014;59:1393–1405.
 7. Chen L, Zhou T, Wu N, et al. Pinealectomy or light exposure exacerbates biliary damage and liver fibrosis in cholestatic rats through decreased melatonin synthesis. *Biochim Biophys Acta Mol Basis Dis* 2019;1865:1525–1539.
 8. Tabibian JH, O'Hara SP, Splinter PL, et al. Cholangiocyte senescence by way of N-ras activation is a characteristic of primary sclerosing cholangitis. *Hepatology* 2014;59:2263–2275.
 9. Sato K, Meng F, Giang T, et al. Mechanisms of cholangiocyte responses to injury. *Biochim Biophys Acta* 2018;1864(4 Pt B):1262–1269.
 10. Prakoso E, Tirnitz-Parker JE, Clouston AD, et al. Analysis of the intrahepatic ductular reaction and progenitor cell responses in hepatitis C virus recurrence after liver transplantation. *Liver Transpl* 2014;20:1508–1519.
 11. Atkinson SR, Aly M, Remih K, et al. Serum keratin 19 (CYFRA21-1) is a prognostic biomarker in severe alcoholic hepatitis. *Liver Int* 2022;42:1049–1057.
 12. Xu M, Xie F, Qian G, et al. Peritumoral ductular reaction: a poor postoperative prognostic factor for hepatocellular carcinoma. *BMC Cancer* 2014;14:65.
 13. Wu N, Meng F, Zhou T, et al. The secretin/secretin receptor axis modulates ductular reaction and liver fibrosis through changes in transforming growth factor-beta1-mediated biliary senescence. *Am J Pathol* 2018;188:2264–2280.
 14. Kyritsi K, Francis H, Zhou T, et al. Downregulation of p16 decreases biliary damage and liver fibrosis in the *Mdr2*^{-/-} mouse model of primary sclerosing cholangitis. *Gene Expr* 2020;20:89–103.
 15. Zhou T, Kyritsi K, Wu N, et al. Knockdown of vimentin reduces mesenchymal phenotype of cholangiocytes in the *Mdr2*^{-/-} mouse model of primary sclerosing cholangitis (PSC). *EBio-Medicine* 2019;48:130–142.

Correspondence

Address correspondence to: Keisaku Sato, PhD, Indiana Center for Liver Research, Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, 702 Rotary Circle, RO 009, Indianapolis, Indiana 46202. e-mail: keisato@iu.edu.

Conflicts of interest

The authors disclose no conflicts.

Funding

This work was supported by the Hickam Endowed Chair, Gastroenterology, Medicine, Indiana University, the Indiana University Health – Indiana University School of Medicine Strategic Research Initiative, the Senior Career Scientist Award (IK6BX004601), and the VA Merit award (5I01BX000574) to GA and the Career Scientist Award (IK6BX005226) and the VA Merit award (1I01BX003031) to HF from the United States Department of Veteran's Affairs, Biomedical Laboratory Research and Development Service; NIH grants DK108959 and DK119421 (HF), DK054811, DK115184, DK076898, DK107310, DK110035, DK062975, and AA028711 (GA and SG); and the PSC Partners Seeking a Cure (GA). Portions of these studies were supported by resources at Richard L. Roudebush VA Medical Center, Indianapolis, Indiana, and Medical Physiology, Medical Research Building, Temple, Texas. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs.